Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taragarestrant (D-0502) +/- Palbociclib in Advanced ER+/HER2- Breast Cancer
NCT03471663Phase 1Completed
- Sponsor
- InventisBio
- Start
- Mar 2018
- Primary completion
- Oct 2023
- Modality
- Molecular Glues
- Countries
- 2
01
Overview
Phase 1, open-label trial of taragarestrant in estrogen receptor-positive breast cancer (ER+) (2 arms), sponsored by InventisBio. Primary endpoint: Incidence of Adverse Events meeting Dose-Limiting Toxicities criteria at 2 years. Started Mar 2018; status: completed.
02
Drugs
taragarestrant
03
Conditions
estrogen receptor-positive breast cancer (ER+)
Beyond the preview
Go deeper on NCT03471663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03471663.